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Abstract
Background: Patients with head and neck cancer (HNC) are vulnerable to fear of
cancer recurrence (FCR) and psychiatric morbidity. We investigated the prevalence
of high FCR and demographic, clinical, psychological, and psychiatric factors asso-
ciated with high FCR prior to the start of the treatment.
Methods: In a cross-sectional substudy of the large ongoing prospective NET-
QUBIC study questionnaires and psychiatric interviews of 216 patients newly diag-
nosed with HNC were analyzed.
Results: High FCR was observed in 52.8% of patients and among those 21.1% also
had a lifetime history of selected anxiety or major depressive disorder. FCR was
not related to any clinical characteristics; however, younger age, higher anxiety
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symptoms, introversion, greater needs for support regarding sexuality, and being an
exsmoker were significantly associated with higher FCR.
Conclusion: Factors associated with high FCR provide us with a better conceptual
understanding of FCR in patients newly diagnosed with HNC.
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1 | INTRODUCTION
Head and neck cancer (HNC) includes a range of tumors that
arise in oral cavity, pharynx, larynx, nasal cavity, paranasal
sinuses, and salivary glands. Each year, HNC accounts for
more than 550 000 new diagnoses and 380 000 deaths
worldwide.1 In the Netherlands, about 3000 people are diag-
nosed with HCN annually.2 Past research demonstrates that
patients with HNC are particularly vulnerable to develop
fear of cancer recurrence (FCR), defined as “fear, worry, or
concern relating to the possibility that cancer will come back
or progress,”3 with between 31% and 83% of patients
reporting elevated levels of FCR.4-8 Moreover, FCR has
been consistently reported as one of the most prevalent
unmet needs for help of cancer survivors in various cancer
types9-11 and one of the most common concerns that patients
with HNC wish to discuss in specialist consultations.12
The model of Lee-Jones et al13 offers a good theoretical
basis for understanding patients' reactions and fears about
the possibility of cancer progression or cancer coming back.
This model proposes that patients' fear might be triggered by
cognition and emotions caused by internal cues (eg, physical
symptoms) and/or external cues (eg, doctors' appointments).
Fear can further be caused by specific behaviors such as
seeking advice at health professionals and personal checking
behavior or psychological effects such as misinterpretation
of symptoms or an increase in somatic anxiety. Patients with
HNC within 5 years have a significant chance to relapse.14
Patients newly diagnosed with HNC have frequent medical
consultations and exams in the diagnosis phase and exten-
sive treatment involving higher level of physical symptoms
(eg, pain, sore dry mouth, and throat),15 providing an under-
standable basis for FCR.
However, similar to studies involving patients with other
cancer types, most longitudinal and cross-sectional studies in
patients with HNC fail to find an association between FCR
and objective indices of poor prognosis (eg, tumor site and
tumor stage).6,7,12,16,17 Treatment-, symptom-, and patient-
related factors appear to be more important determinants of
FCR. Although there is some evidence on various factors
associated with FCR in HNC, most of these findings were
derived from patients in the active treatment or posttreatment
survivorship phase and less is known on how these factors are
associated in the patients newly diagnosed with HNC. Albeit
patients newly diagnosed with cancer might be more fearful
about progression rather than recurrence, the definition of
FCR encompasses both the possibility that cancer will pro-
gress as well as that it might come back.3 Moreover, high
levels of FCR have been identified as soon as prior to the
treatment,18 which points out that worries about recur-
rence/progression can occur early in the cancer trajectory.
Previous studies involving patients with HNC suggest a
significant relationship between FCR and younger age, hav-
ing chemotherapy or radiotherapy, physical symptoms (eg,
pain), disfigurement, psychological factors (including symp-
toms of anxiety and depression), and lifestyle factors (eg,
smoking).4,6,7,12,16,19 High levels of FCR have been consis-
tently associated with poorer QoL in patients with HNC.4,16,20
However, it is noteworthy that the majority of studies to date
on FCR and various variables in HNC are cross-sectional and
involve relatively small samples. Moreover, there is currently
no evidence on how FCR and personality, fatigue, and
cancer-specific distress (eg, intrusion and avoidance) are con-
nected in patients with HNC; however, outside of HNC, stud-
ies with other types of patients with cancer suggest that
higher levels of intrusive stress symptoms, neuroticism, and
fatigue are related to higher FCR.21-23 There are currently no
studies addressing the association between FCR and unmet
needs in patients with HNC; however, a study of mixed can-
cer survivors indicated that higher FCR was associated with
all five unmet supportive care needs, including needs regard-
ing health system and information, sexuality, patient care,
physical and daily living, and psychological needs.24
Many previous studies among patients with HNC showed
a relationship between FCR and psychological symptoms
(eg, anxiety and depression).5-7,12,19 Psychological distress is
usually assessed by self-reported questionnaires, mostly the
Hospital Anxiety and Depression Scale (HADS), which is a
frequently used screening tool in HNC research for detecting
symptoms of anxiety and depression.25,26 However, there is
a lack of consensus on an optimal cutoff score for identify-
ing probable clinical cases of anxiety and depression (the
cutoff score ranges from a low of 5 to high of 11).25 The
golden standard for identifying psychiatric morbidity is
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considered to be psychiatric interviews. Several studies in
patients with various cancer types have explored the relation-
ship between FCR and psychiatric disorders and showed that
the presence of anxiety disorders21,27 and post-traumatic stress
disorder (PTSD) symptoms,28 was positively associated with
FCR. Simard et al22 found that as FCR severity increases,
intrusive thoughts appear more like obsessions (as seen in the
obsessive-compulsive disorder). However, studies have found
that only 16%-43% of patients with high FCR have a comor-
bid psychiatric disorder,21,27,29-33 suggesting that FCR is an
independent entity that needs to be studied as a separate con-
struct. Importantly, none of those reported studies focused
specifically on patients with HNC. Data suggest that patients
with HNC report the second highest prevalence of any mental
disorders among all cancer types, with a 4-week DSM-IV
overall disorder prevalence of 41% and 12-month prevalence
of 39%.34,35 Therefore, understanding the relationship
between FCR and psychiatric morbidity in this cancer patient
subgroup is of particular importance.
HNC, its recurrence, and mortality are strongly associated
with environmental and lifestyle risk factors like tobacco and
excessive alcohol consumption.36 Although few studies have
investigated the relationship between FCR and tobacco use,
those conducted to date reported a positive association
between high FCR and increased tobacco use,20 and that
exsmokers with higher FCR were more likely to relapse by
12 months follow-up.37 Similarly, successful smoking cessa-
tion might also be related to reduced FCR, with one prospec-
tive study of 73 patients with HNC showing that those who
quit smoking during the first 15 months after diagnosis had
significantly less FCR compared with those who continued to
smoke or who relapsed.19 Further research is needed to under-
stand this complex relationship between smoking and FCR in
patients newly diagnosed with HNC.
The prevalence rate of elevated FCR among patients with
HNC is reported to be high (>30%),4-8 however only two
studies have been conducted in patients newly diagnosed
with HNC, with varying estimates ranging from 31%5 to
62% using varying measures of FCR.8 Importantly, only a
study from Savard and Ivers reported a validated cutoff
score of 13.8 In accordance with Lee-Jones's FCR model,
the presence of physical symptoms associated with HNC
and the frequency of medical consultation and exams in the
diagnosis phase could lead to a higher FCR in this popula-
tion. Due to the FCR's negative impact on well-being, there
is a growing need to identify factors associated with high
FCR in HNC, especially in patients newly diagnosed with
HNC, so that appropriate supportive care interventions can
be designed and offered to those patients with HNC who
need it. Therefore, the purpose of this study was to explore
the prevalence of FCR and the strength of association
between FCR and psychiatric disorders (selected anxiety
and major depressive disorder), and demographic, clinical,
psychological, and behavioral features associated with FCR
in a representative cohort of newly diagnosed Dutch patients
with HNC. The current study was exploratory and variables
introduced above were chosen based on factors associated
with high FCR in the past literature.17 Therefore, the objective
of this study was to: (a) explore the prevalence and psychiat-
ric morbidity of patients with HNC experiencing high FCR
and (b) assess the potential factors associated with FCR in
patients with HNC.
2 | PATIENTS AND METHODS
2.1 | Patients and procedure
This study was conducted using baseline data (before start
of the treatment) of the first 254 patients newly diagnosed
with HNC from a large ongoing prospective cohort study
investigating the long-term course of quality of life (QoL) in
patients with HNC and their caregivers (NET-QUBIC study;
www.kubusproject.nl). The present sample consisted of only
patients newly diagnosed with HNC who completed baseline
assessment of FCR (N = 216).
Study participants were recruited between March 2014
and July 2016 in the five medical centers in the Netherlands
(VU University Medical Centre Amsterdam [VUmc], Uni-
versity Medical Center Groningen, Radboud University
Medical Center Nijmegen, University Medical Center
Utrecht, and Erasmus Medical Center Rotterdam). Every
new patient with HNC was screened for eligibility. Eligible
patients were 18 years or older, newly diagnosed with HNC
(oral, oropharynx, hypopharynx, larynx, unknown primary;
all stages), previously untreated and with plans for treatment
with curative intent according to standard treatment guide-
lines, and able to write, read, and speak fluent Dutch. Exclu-
sion criteria were malignancies of the salivary glands,
nasopharyngeal malignancies, lymphoma, skin malignan-
cies, thyroid cancer, and patients with severe psychiatric
comorbidities which could impair the ability to give
informed consent (eg, schizophrenia, Korsakoff's syndrome,
and severe dementia). Patients with severe psychiatric diffi-
culties were excluded based on the professional expertise of
the physician or nurse involved in the recruitment of
patients, and in consultation with the treating physician. Eli-
gible patients were invited to participate by the treating sur-
geon, and the research physician provided them with more
information about the study and with written information.
All patients that agreed to participate signed a written con-
sent. Ethical approval was obtained by the coordinating cen-
ter (METc VUmc 2013.301), and local approval was
obtained individually with each medical center. A more
detailed explanation about the procedure and recruitment is
explained elsewhere.38
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2.2 | Methods
Assessments were conducted at the hospital and/or the
patient's home. Assessments included patient reported out-
comes, interviews, and medical examinations.38
Fear of recurrence was measured using the Cancer Worry
Scale (CWS), which is a reliable and valid self-reported
8-item scale.39 It measures worry about the risk of cancer
recurrence and its impact on daily functioning. Total score
ranges from 8 to 32. Higher scores indicate higher FCR.
A cutoff score of 13 vs 14 (low FCR: ≤13, high FCR: ≥14)
has been established to differentiate between those with nor-
mal FCR from those with bothersome levels of FCR (hence-
forth referred to as high FCR).39 This cutoff has been
validated relative to the Fear of Cancer Recurrence Inventory
cutoff score, which is validated measure.40 The Dutch version
of the CWS is reliable (Cronbach's α = .87 and .89) and has
been validated in various cancer populations.40,41 Internal
consistency in the present sample was high (Cronbach's
α = 0.90; 95% confidence interval = 0.88, 0.92).
Demographic and clinical characteristics were collected
in self-report questionnaires and medical records. Demo-
graphic characteristics included age, sex, education, and
living arrangement (coded as alone or cohabiting). Disease-
related characteristics included tumor location, tumor stage
(from 0 to II coded as early and from III to IVB as late), time
since diagnosis (measured in days), and World Health Orga-
nization performance status (0, able to carry all normal activ-
ity without restriction; 1, restricted in physical strenuous
activity but ambulatory and able to carry out light work;
2, ambulatory and capable of all self-care but unable to carry
out any work). Data for physical comorbidity were assessed
by the Adult Comorbidity Evaluation-27 Index,42 which is a
validated comorbidity instrument with a 27 items and 12 cat-
egories (eg, cardiovascular and body weight). For the analy-
sis, only item severity was used. This item is originally
coded as none, mild, moderate, and severe; however, we
have categorized it as none-mild or moderate-severe.
Substance use regarding alcohol and nicotine was
assessed using study-specific items. Alcohol was analyzed as
a continuous variable (number of alcohol beverages on a typi-
cal day) and smoking status was coded as smoking at the time
of assessment (yes/no) or in the past (no, but I smoked in
the past).
Psychiatric morbidity represented by the presence of
lifetime depressive (major depressive disorder) and selected
anxiety (panic disorder, social phobia, generalized anxiety dis-
order [GAD], and agoraphobia) disorders was assessed with
the Composite International Diagnostic Interview (CIDI),
which is based on the DSM-IV criteria. Although the CIDI
can assess current and lifetime disorders, only lifetime disor-
ders were assessed for this study. The lifetime CIDI allowed
for the determination of the history, recency (ie, within last
week and more than 1 year ago), duration, and age of onset of
episodes of selected anxiety and major depressive disorder.43
Fieldworkers from different backgrounds (eg, nurse, dietician,
psychologist, and laboratory technician) were trained to
conduct the CIDI in a standardized way. Additionally, all
CIDI interviews were recorded and the coordinating field
worker randomly checked and supervised for their quality.
Patients were coded into the two groups: (a) no CIDI life-
time anxiety or major depressive disorder and (b) CIDI life-
time anxiety or major depressive disorder.
Cancer-specific distress was assessed by the Impact of
Event Scale-Revised, which is a 22-items scale44 and includes
subscales of intrusion, sleep disturbance, hyperarousal, avoid-
ance, and numbing. Items are scored on a 5-point scale, rang-
ing from 0 (“not at all”) to 4 (“extremely”). For the analysis,
only subscale scores for intrusion and avoidance were used
(8 items for avoidance and 7 items for intrusion), as those two
appear to be most commonly associated with high FCR.45
The scale is well validated in the Netherlands, and Cronbach's
alpha in the Dutch patients with cancer was reported to be .85
for avoidance and .92 for intrusion.46
Psychological distress expressed in symptoms of anxiety
and depression was assessed with the HADS,47 which includes
14 items that are divided into two subscales: depression
and anxiety. The maximum score on each subscale is 21
and higher score suggests elevated symptomatology. Internal
consistency in the Dutch patients with cancer showed an
adequate value (α coefficient was .89 for anxiety and .78 for
depression).46 We have analyzed only scores for anxiety and
depression and not the total distress scores.
QoL was assessed using 2 of the 6 functional scales from
the core module of the EORTC QoL questionnaire (EORTC
QLQ-C30). Based on a team discussion and literature review,
only physical functioning and global QoL subscale scores
were used.40 A Dutch version tested in patients with cancer
showed a Cronbach's α = .80 for physical functioning and .86
for global QoL.48,49
Supportive care needs were assessed using the Supportive
Care Needs Survey Short-Form 34 (SCNS-SF34), which is a
34 item measure that evaluates patient's need for supportive
care with respect to physical and daily living, psychological,
sexuality, patient care and support, and health system and
information needs.50 In addition, a 1-item specific HNC issues
subscale was used from the SCNS-HNC, which assesses
problems such as chewing/swallowing, speech, and hearing.51
Lifestyle subscale was not included in the analysis, because
we had assessed drinking and smoking problems separately
(see demographic and clinical characteristics above). Evi-
dence supports the validity and reliability of the Dutch ver-
sions of the SCNS-SF34 (α = .79-.95) and SCNS-HNC
(α = .89 for specific HNC issues).51
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TABLE 1 Clinical and demographic characteristics
Characteristics CWS completersa CWS noncompletersb P valuec
No. of patients 216 38
Age at diagnosis (mean ± SD, range) 62.3 ± 9.7, 37-85 60.7 ± 10.8, 41-84 .36
Sex (n, %)
Female 66 (30.6) 6 (15.8) .06
Male 150 (69.4) 32 (84.2)
Living arrangement (n, %)
Alone 40 (18.5) 13 (34.2) .12
Cohabiting 143 (66.2) 21 (55.3)
Missing 33 (15.3) 4 (10.5)
Educational status (n, %)
Primary education 10 (4.6) 3 (7.9) .98
Lower or preparatory vocational education 45 (20.8) 8 (21.1)
Intermediary general secondary education 27 (12.5) 6 (15.8)
Senior general secondary education 34 (15.7) 6 (15.8)
Higher general secondary education 19 (8.8) 4 (10.4)
Higher professional education 33 (15.3) 5 (13.2)
University 14 (6.5) 2 (5.3)
Missing 34 (15.7) 4 (10.5)
Smoking status (n, %) .88
Regular smoker 55 (25.5) 1 (2.6)
Occasional smoker 11 (5.1) 0
Smoker in the past 113 (52.3) 5 (13.2)
Never smoked 34 (15.7) 1 (2.6)
Missing 3 (1.4) 31 (81.6)
Alcohol (no. of beverages on a typical day) .99
M ± SD, range 3.0 ± 3.8, 0-28 3.0 ± 1.4, 0-4
Missing (n, %) 23 (10.6) 31 (81.6)
Time since diagnosis (days) (n, %) 21.3 (18.6) 13 (9.0) .24
Missing (n, %) 3 (1.4) 31(81.6)
Tumor site (n, %) .50
Oral cavity 65 (30.1) 7 (18.4)
Oropharynx 74 (34.3) 15 (39.5)
Hypopharynx 18 (8.3) 5 (13.2)
Larynx 55 (25.5) 11 (28.9)
Unknown primary 4 (1.9) 0
Tumor stage (n, %) .42
Early stage 89 (41.2) 13 (32.2)
Late stage 127 (58.8) 25 (65.8)
WHO performance status (n, %) .79
0d 153 (74.3) 28 (73.7)
1e 53 (24.8) 8 (21.1)
3f 8 (3.7) 2 (5.3)
(Continues)
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TABLE 1 (Continued)
Characteristics CWS completersa CWS noncompletersb P valuec
ACE-27 comorbidity scale (n, %) .21
None-mild 133 (61.6) 26 (68.4)
Moderate-severe 70 (32.4) 8 (21.1)
Missing 13 (6.0) 4 (10.5)
PASE, physical activity (M ± SD) 101 ± 82.8 84.8 ± 40.6 .64
Missing (n, %) 1 (0.5) 32 (84.2)
BPI, mean severity pain (M ± SD) 4 ± 2 4.1 ± 2.0 .95
Missing (n, %) 135 (62.5) 22 (57.9)
MFI, general fatigue (M ± SD) 10.9 ± 4.8 8.4 ± 2.4 .04
Missing (n, %) 4 (1.9) 31 (81.6)
HADS, anxiety (M ± SD) 6.0 ± 4.0 6.8 ± 4.7 .63
Missing (n, %) 11 (5.1) 32 (84.2)
HADS, depression (M ± SD) 4.3 ± 3.6 5.7 ± 5.8 .59
Missing (n, %) 9 (4.2) 32 (84.2)
IES-R intrusion (M ± SD) 4.9 ± 4.9 8.7 ± 5.2 .05
Missing (n, %) 8 (3.7) 31 (81.6)
IES-R avoidance (M ± SD) 3.8 ± 4.2 7.6 ± 4.2 .02
Missing (n, %) 12 (5.6) 31 (81.6)
EORTC, physical functioning (M ± SD) 58.6 ± 18.4 97.9 ± 5.3 .001
Missing (n, %) 9 (4.2) 32 (84.2)
EORTC, global quality of life (M ± SD) 68.9 ± 18.7 79.0 ± 6.7 .01
Missing (n, %) 9 (4.2) 32 (84.2)
NEO-FFI, neuroticism (M ± SD) 28.3 ± 7.5 28.1 ± 2.5 .89
Missing (n, %) 3 (1.4) 31 (81.6)
NEO-FFI, extraversion (M ± SD) 39.9 ± 6.9 38.0 ± 3.8 .48
Missing (n, %) 3 (1.4) 31 (81.6)
SCNS-SF34, physical and daily living (M ± SD) 17.5 ± 23.1 23.6 ± 31.1 .50
Missing (n, %) 9 (4.2) 31 (81.6)
SCNS-SF34, psychological (M ± SD) 28.0 ± 24.6 36.1 ± 29.7 .40
Missing (n, %) 9 (4.2) 31 (81.6)
SCNS-SF34, sexuality (M ± SD) 12.9 ± 20.4 10.7 ± 18.5 .78
Missing (n, %) 10 (4.6) 31 (81.6)
SCNS-SF34, health system, information, and patients support (M ± SD) 30.1 ± 21.6 26.4 ± 22.2 .66
Missing (n, %) 10 (4.6) 31 (81.6)
SCNS-HNC, head and neck cancer-specific functioning (M ± SD) 15.4 ± 17.0 7.6 ± 15.0 .23
Missing (n, %) 10 (4.6) 31 (81.6)
Abbreviations: ACE-27, Adult Comorbidity Evaluation-27 Index; BPI, Brief Pain Inventory; CWS, Cancer Worry Scale; FCR, fear of cancer recurrence;
HADS, Hospital Anxiety and Depression Scale, IES-R, Impact of Event Scale-Revised; MFI, Multidimensional Fatigue Inventory; NEO-FFI, FIVE Factor Inventory;
PASE, Physical Activity Scale for the Elderly; SCNS-HNC, Supportive Care Needs Survey-HNC; SCNS-SF34, Supportive Care Needs Survey Short-Form 34;
WHO, World Health Organization.
aPatients who completed primary outcome.
bPatients who did not complete the primary outcome.
cBased on t tests (for continuous variables) and chi-square or Fischer test (for categorical variables).
dAble to carry out all normal activity without restriction.
eRestricted in physical strenuous activity but ambulatory, able to carry out light work.
fAmbulatory and capable of all self-care but unable to carry out any work.
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Personality factors were assessed using the FIVE Factor
Inventory,52 which measures five dimensions of personality:
neuroticism, extraversion, openness to experience, agreeable-
ness, and conscientiousness. Each dimension consists of
12 items. In the Dutch patients with cancer, Cronbach's alpha
showed a satisfactory result (.73-.86).53 Based on a team dis-
cussion and literature review, only neuroticism and extraver-
sion were included.
Physical symptoms and functioning were assessed with the
following measures. For fatigue, Multidimensional Fatigue
Inventory54 was used, which is a 20-item self-reported mea-
sure covering various dimensions of fatigue (ie, general, phys-
ical, mental fatigue, reduced motivation, and activity). For the
analysis, the total score was used. Cronbach's alpha in the
Dutch patients with cancer was reportedly adequate (.84).
Physical activity was assessed with the Physical Activity
Scale for the Elderly, which is a 10-item questionnaire that
measures activity levels over a timeframe of 1 week, ranging
from 0 to 739 (higher score indicating greater physical activ-
ity).55 Finally, pain was measured by the Brief Pain Inventory
(BPI), which assesses the types of pain, pain history, intensity,
location, quality, and the degree of pain interference with
activities of daily life.56 For the analysis with FCR, only one
question was selected from the BPI (the mean severity pain).
2.3 | Statistical analysis
Data were analyzed using SPSS version 22. Scores on self-
reported questionnaires and missing values were treated
according to their manuals. The primary outcome was CWS
score. Data on CIDI were analyzed only for the bivariate com-
parison of mean CWS with the CIDI lifetime anxiety or depres-
sive disorder and were not included in the multivariate analysis.
Responders and nonresponders to the CWS were com-
pared on age, clinical variables, anxiety and depression symp-
toms, and sex to examine whether there were significant
differences between groups (Table 1). After eliminating CWS
nonresponders from the analysis, descriptive statistics were
used to explore the distribution of the data and to report the
prevalence of high FCR (≥14) and the relationship between
CIDI psychiatric morbidity and high FCR.
The relationship between CIDI psychiatric morbidity and
FCR was calculated by comparing mean CWS scores
between no CIDI lifetime selected anxiety or major depres-
sive disorder and CIDI lifetime selected anxiety or major
depressive disorder.
The distribution of CWS scores and residuals were exam-
ined for normality. After confirming that CWS scores were
normally distributed, age-adjusted univariate linear regression
was used to explore the association between potential predic-
tor variables and FCR. Univariate tests were age-adjusted
because younger age has been shown to be the most
consistent predictor of elevated FCR.45 In the multivariate
models, tolerance statistics and variance inflation factor of
each potential predictor and the correlations among the pre-
dictors were examined to identify and address potential
multicollinearity issues in the model. Potential predictors (ie,
those significant in univariate tests at the P < .2 level) were
entered into stepwise linear regression models, first
sociodemographic, then clinical, psychological, and behav-
ioral characteristics. Variables were retained in the penulti-
mate model if they were significant at the P < .1 level. A
final linear regression model was then used to examine the
unique effects of modifiable psychological and behavioral
characteristics on FCR when controlling for all previously sig-
nificant clinical and demographics factors in addition to age.
Variables in the final model were considered significant
if P < .05.
3 | RESULTS
The response rate of the baseline early release NET-QUBIC
data is 39%. Therefore, 254 baseline questionnaires were
received. However, as FCR was our main outcome,
38 patients (15%) that did not complete the CWS or had too
many missing items to calculate a total score of CWS
(Table 1) were excluded from the analysis, resulting in a sam-
ple of 216 patients for the present analysis. A higher propor-
tion of males (84.8% vs 69.4%, P = .06) and those living
alone (34.3% vs 18.5, P = .12) completed the CWS, but these
differences were not statistically significant (Table 1). Further-
more, there were no statistically significant differences found
between completers and noncompleters of the CWS on other
sociodemographic, clinical, or psychological characteristics.
3.1 | Patients characteristics
Sociodemographic and clinical characteristics of the sample are
shown in Table 1. Patients' mean age was 62.3 years (SD = 9.7),
69.4% of the sample represented males, and 66.2% of the
patients were cohabiting with a partner or other person. Patients
were diagnosed with oropharynx (34%), oral cavity (30%), lar-
ynx (26%), or hypopharynx (8%), and the majority were diag-
nosed in the late stage of the disease (59%). The majority
(71.6%) had a good performance status (ie, were able to carry
out normal activity) and 34.5% had moderate to severe comor-
bidity at the time of the study, which appears to be high.57
3.2 | Prevalence of FCR and its severity
High FCR (ie, CWS score ≥ 14) was reported by 114 (52.8%)
patients. Mean CWS score was 14.25 (SD = 4.6) for the entire
sample, 17.7 (3.6) for participants with high FCR, and 10.5
(1.7) for those with low FCR.
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TABLE 2 Results of age-adjusted associations of all potential predictors with FCR score (CWS-total) for patients newly diagnosed with
HNC (n = 216)
Variable Beta t P
Sex .337 0.502 .62
Education (dummy coded, “Primary” set as a reference variable) .18 (overall model)
Primary (ref)
Lower or preparatory vocational .159 0.161 .87
Intermediary general secondary −.276 −0.246 .81
Senior general secondary −.625 −0.595 .55
Higher general secondary −.182 −0.145 .88
Higher professional .754 0.710 .48
University −.429 −0.305 .76
Living arrangement
Alone
Cohabiting −.443 −0.524 .60
Smoking (dummy coded, Yes, I smoke every day set as a reference variable) .008 (overall model)
No, but I smoked in the past (ref)
No −.126 −1.803 .07
Yes, I smoke every day −.071 −1.009 .31
Alcohol (no. of beverages on a typical day) −.028 −0.317 .75
Time since diagnosis (days) −.221 −1.161 .25
Tumor site (dummy coded, “Oropharynx” set as a reference variable) .07 (overall model)
Oropharynx (ref)
Oral cavity .635 0.821 .41
Hypopharynx 1.053 0.878 .38
Larynx .961 1.178 .24
Unknown primary 1.064 0.455 .65
Tumor stage
Early
Late .301 0.476 .63
EORTC, physical functioning −.033 −1.865 .06
EORTC, global quality of life −.077 −4.735 <.001
NEO-FFI, neuroticism .230 5.969 <.001
NEO-FFI, extraversion −.159 −3.517 .001
SCNS-SF34, physical and daily living .031 2.374 .02
SCNS-SF34, psychological .084 7.367 <.001
SCNS-SF34, sexuality .058 3.973 <.001
SCNS-SF34, health system, information, and patients support .051 3.851 <.001
SCNS-HNC, Head and neck cancer-specific functioning .047 2.743 .007
PASE physical activity .002 0.525 .60
IES-R intrusion .327 5.510 <.001
IES-R avoidance .369 5.220 <.001
HADS, depression .541 6.751 <.001
HADS, anxiety .734 11.777 <.001
(Continues)
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3.3 | Stepwise regression model: variables
associated with FCR
Results of age-adjusted univariate regressions are presented
in Table 2. Briefly, when controlling for age, patients with
HNC with higher FCR were more likely to be exsmokers,
have restricted physical strenuous activity, worse QoL (only
global QoL), higher neuroticism and introversion, and
higher level of unmet needs in each of the five unmet need
domains. Patients with HNC with higher FCR were also
more likely to report higher levels of cancer-specific intru-
sion and avoidance symptoms, higher symptoms of depres-
sion and anxiety, higher mean pain severity, and higher
fatigue. There were no significant associations with self-
reported physical activity, or with any of the demographic or
clinical variables assessed.
Significant predictors in age-adjusted analyses were selected
for further examination in multivariate models. The results of
the final model are shown in Table 3. Higher FCR levels were
significantly associated with younger age (β = .203, P < .001),
introversion (β = .115, P < .05), more symptoms of anxiety
(β = .578, P < .001), having higher levels of unmet needs for
help with sexual issues (β = .182, P = .001) and being an
exsmoker (β = .130, P < .05). The model was found to be
statistically significant (F [7, 185] = 24.724, P < .001) and
explained 46.4% of the variance in FCR in patients with
HNC. The strongest predictors of higher FCR were higher
anxiety (HADS-A) scores and younger age.
3.4 | Prevalence of selected lifetime psychiatric
disorders and overlap with high FCR
The analysis of lifetime psychiatric disorders is based on
178 patients for whom data on CIDI anxiety disorders
(including GAD, social phobia, panic disorder, and agora-
phobia) and major depressive disorder and CWS scores were
available. Patients for whom selected psychiatric disorders
were available did not differ from patients for whom selected
disorders were not available on any of the demographic or
clinical characteristics (data not shown). The prevalence of
selected lifetime CIDI anxiety disorders was 8.4% (n = 15),
and 11.2% (n = 20) for CIDI major depressive disorder (see
the Methods section for subtypes), however as some patients
were found to have both (combined CIDI), the prevalence of
having a lifetime history of either a lifetime selected anxiety
or major depressive disorder was 16.3% (n = 29). Table 4
presents the group differences in means for CWS for patients
with (a) no CIDI diagnosis vs (b) those diagnosed with
selected CIDI anxiety disorders or major depression. Patients
with a lifetime history of either selected anxiety or major
TABLE 2 (Continued)
Variable Beta t P
BPI, mean pain severity .389 2.748 .007
WHO performance (dummy coded, “Able to carry” set as a reference) .01 (overall model)
Able to carry all normal activity without restriction (ref)
Restricted in physical strenuous activity but ambulatory and able to carry out light work 1.195 1.654 .10
Ambulatory and capable of all self-care but unable to carry out any work .532 0.325 .75
Comorbidity
None-mild
Moderate-severe .703 1.026 .31
MFI general fatigue .207 3.294 .001
Abbreviations: BPI, Brief Pain Inventory; CWS, Cancer Worry Scale; FCR, fear of cancer recurrence; HADS, Hospital Anxiety and Depression Scale, HNC, head and
neck cancer; IES-R, Impact of Event Scale-Revised; MFI, Multidimensional Fatigue Inventory; NEO-FFI, FIVE Factor Inventory; PASE, Physical Activity Scale for
the Elderly; SCNS-HNC, Supportive Care Needs Survey-HNC; SCNS-SF34, Supportive Care Needs Survey Short-Form 34; WHO, World Health Organization.
TABLE 3 Linear regression model predicting FCR scores
Predictors Beta t P
Age −.203 −3.692 >.001
HADS, anxiety .578 10.477 >.001
NEO-FFI, introversion .115 2.040 .04
SCNS-SF34, sexuality .182 3.357 .001
Smoking status
Regular smoker (ref)
Occasional smoker .014 0.252 .88
Smoker in the past .130 2.038 .04
Never smoked .009 0.146 .80
Notes. R = 0.695; R2 = 0.483; adjusted R2 = 0.464; SE of the estimate = 3.297.
Beta is standardized regression coefficient.
Abbreviations: FCR, fear of cancer recurrence; HADS, Hospital Anxiety and
Depression Scale, NEO-FFI, FIVE Factor Inventory; SCNS-SF34, Supportive
Care Needs Survey Short-Form 34.
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depressive disorder reported significantly higher FCR than
those without a diagnosis (F = .768, P = .006).
Figure 1 illustrates the percentage of patients with low
FCR and lifetime selected anxiety or major depressive disor-
der, and patients with high FCR and concurrent selected psy-
chiatric disorders. Among patients with high FCR and for
whom data for selected psychiatric morbidity was available
(n = 90), 21.1% (n = 19) of the patients had a lifetime
selected anxiety or major depressive disorder, which means
that almost 80% of the patients with high FCR did not have
lifetime selected psychiatric disorders. In the group of low
FCR, there were 10 out of 29 patients (34%) with concurrent
selected psychiatric disorder (Figure 1). There were no sta-
tistically significant differences found between the propor-
tion of patients with high vs low FCR (21.1% vs 11.4%;
P = .08) reporting lifetime selected psychiatric morbidity.
4 | DISCUSSION
This study reports baseline data from the NET-QUBIC
study, an ongoing prospective population-based cohort study
in patients newly diagnosed with HNC. Approximately half
(52%) of the patients reported high FCR. Being younger,
more introverted, having higher levels of unmet needs for
help with sexual issues, higher symptoms of anxiety, and
being an exsmoker were identified as factors associated with
high FCR. Patients with a lifetime history of selected anxiety
disorders and major depressive disorder reported signifi-
cantly higher levels of FCR (severity) than those without it;
however, it is noteworthy that the majority of patients with
high FCR did not additionally meet that criteria for a lifetime
history of a selected anxiety or major depressive disorder,
suggesting that while FCR may be associated with psycho-
pathology, it is a distinct problem for the majority of HNC
and therefore warrants specific attention.
The prevalence of high FCR in patients newly diagnosed
with HNC in the present study is consistent with past literature
in patients newly diagnosed with HNC, which reports preva-
lence rates ranging widely from 31%5 to 62%.8 However, two
previous studies have used a variety of instruments to measure
FCR and a variety of definitions of high FCR, therefore draw-
ing comparisons with these studies is difficult. The high preva-
lence found in our study may, in part, be explained by the fact
that our sample involved patients newly diagnosed with HNC
who are unaware of the severity of their diagnosis, which may
increase feelings of uncertainty. Although future longitudinal
assessments will further screen how the prevalence changes
through time, a prospective study by Savard and Ivers reported
that a small sample of patients with HNC presented a stable
pattern of elevated FCR across all six time points during the
18-month follow-up (60%-66%).8
Several demographic and psychological characteristics
emerged as factors associated with FCR. Like previous liter-
ature the present study found an association between high
FCR and younger age.4,6,7,12 With respect to psychological
characteristics (symptoms of anxiety and depression, as mea-
sured with HADS), only symptoms of anxiety were found to
be a significant predictor in the final model. This is in accor-
dance with previous studies that used multivariate analysis
and observed no significant association with depression.17,45
One plausible explanation would be that anxiety is a concept
FIGURE 1 Lifetime psychiatric morbidity and low/high fear of
cancer recurrence (FCR) in patients who completed the Composite
International Diagnostic Interview (CIDI) interviews (n = 178) [Color
figure can be viewed at wileyonlinelibrary.com]
TABLE 4 Comparison of mean (SD) CWS for patients with (a) no CIDI lifetime anxiety or major depressive disorder vs (b) CIDI lifetime
anxiety or major depressive disorder (N = 178)
Measure
No CIDI anxiety or major
depressive disorder (n = 143)
CIDI anxiety or major
depressive disorder (n = 29) P value
CWS (M, SD) 13.73 (4.39) 16.34 (5.60) .006
Abbreviations: CWS, Cancer Worry Scale; CIDI, Composite International Diagnostic Interview.
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different but more closely associated with FCR and particu-
larly with a concept like cancer worry. However, these rela-
tionships may vary over time, and thus this possibility will
be further monitored by the ongoing NET-QUBIC study.
The present study also found that FCR is higher in more
introverted patients. This novel finding might be explained
by the fact that people high on introversion are less likely to
seek social support and help of others when needed.58 Our
results showed that neuroticism was not statistically associ-
ated with FCR in the multivariate models. Furthermore,
other known predictors of high FCR such as intrusive and
avoidant stress symptoms and poor QoL were also not sig-
nificantly associated with higher FCR in the multivariate
model in the present baseline analysis, but will be interesting
to screen over time in future assessments.
An interesting and novel finding was the association
between high FCR and unmet supportive care needs con-
cerning sexuality. Our findings suggest that patients more
fearful of recurrence also have higher levels of unmet needs
for sexual care; but not on other domains of the supportive
care unmet needs. A cross-sectional study of mixed cancer
groups (including HNC) on average 12 months after the diag-
nosis found high FCR to be associated not only with unmet
needs for sexual care, but also with unmet needs with regard
to health system and information, and patient care.24 Our sam-
ple consisted of patients newly diagnosed with HNC who
have just entered the health system, which could to some
degree explain the lack of these findings in our results.
Although we cannot determine direction of the relationship of
the unmet needs on sexual care and high FCR in our sample,
the latter study hypothesized that FCR might interfere with
patients' ability to relax, which might distract them and cause
problems in their intimate relationships.24 Another plausible
explanation would be that FCR affects couples,59 and com-
munication difficulties can arise when both partners are
greatly concerned but not communicating about their fears. In
a couple dyad with high FCR, partners may feel distanced
and isolated from one another in their intimate relationships.
This study provides further evidence of the relationship
between high FCR and tobacco use. These data partly confirm
findings from two other studies of patients with HNC con-
cerning the relationship between smoking behavior and high
FCR.19,37 In our study, high FCR was associated only with
smoking in the past but not current smoking. One plausible
reason could be that exsmokers are more aware of the rela-
tionship between smoking and cancer, hence their efforts to
quit. However, having higher FCR 3 months after initial treat-
ment has been found to predict smoking or relapse to smoking
at 12 months after surgery in previous research,19 raising the
question whether high FCR predisposes exsmokers to
smoking relapse if the problem is not adequately addressed.
Future data analyses might examine whether exsmokers with
high FCR are more likely to relapse to smoking than
exsmokers with lower levels of FCR.
The results suggested significant associations between FCR
and current self-reported anxiety symptoms, as well as with
prior lifetime history of selected anxiety disorders and major
depressive disorder. The majority of patients with high FCR
did not additionally have lifetime selected anxiety and major
depressive disorders, and there was no statistical difference
found between proportion of patients with high vs low FCR
reporting selected lifetime psychiatric morbidity. This is some-
what consistent with previous research which reports a 16%-
43% overlap of FCR scores with screening instruments of psy-
chiatric diagnoses (including GAD and hypochondriasis)31,32
and 7%-40% overlap with structured clinical interviews,
depending on the type of psychiatric morbidity assessed.30,31
However, none of these studies focused specifically on patients
with HNC. Thus, data of the present study at least to some
extent provide further evidence that FCR is a problem which
is distinct from anxiety and depressive disorders for the major-
ity of patients with cancer.31,32 However, it is noteworthy that
only lifetime CIDI was assessed and that patients were
screened only for some types of anxiety disorder (see the
Methods section) and major depressive disorder, therefore it is
not known to what extent high FCR is related to other psychi-
atric disorders (substance dependence, personality disorders,
dysthymic disorder, adjustment disorders, and PTSD) in this
sample. Importantly, patients with severe psychiatric disorders
were excluded from the study (see inclusion/exclusion criteria).
By contrast, when examining psychological symptoms, like
previous studies, the present study found a significant associa-
tion between high FCR and HADS anxiety symptoms in the
final multivariate model. Importantly, the analysis involved
current difficulties as opposed to a prior lifetime history of dif-
ficulties, and therefore offers further evidence that there is
indeed a meaningful overlap between these variables. High
FCR might therefore be a prodromal indicator of a subsequent
anxiety (or major depressive) disorder (and vice versa, ie, post-
diagnosis anxiety or depression as a precursor to high FCR);
however, this hypothesis can be examined in future waves of
data collection within this prospective study.
Some strengths and limitations of the study warrant con-
sideration when interpreting the results. One of the strength of
the study was that the data derived from a multicenter recruit-
ment. Moreover, the present study included a relatively large
and homogenous sample in terms of time of assessment and
phase of treatment. However, homogenous characteristics of
patients could limit the generalizability of the results. Another
limitation is that only lifetime history of selected anxiety dis-
orders and major depressive disorder was assessed and not
current disorders and other psychiatric disorders. Moreover,
the present findings are based on cross-sectional baseline data
precluding drawing conclusions about the causal or temporal
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direction of relationships between higher FCR and the factors
associated with high FCR. Furthermore, due to the large num-
ber of analyses and the exploratory nature of the study, further
data are needed to confirm these results. Future data collection
in the NET-QUBIC project will be used to replicate these
findings, examine the course of high FCR during the first
5 years after diagnosis, and generate a better understanding of
vulnerability factors for high FCR in patients with HNC.
Moreover, in future, wave treatment will have started so we
can look at the impact of treatment and its side effects
on FCR.
It should be noted that one of the questions of the CWS
includes an item relating to the worry about the heredity risk
of cancer, and so it is difficult to consider it for HNC popula-
tion. It is worth mentioning that the item content of the CWS
relates directly only to the cancer recurrence and not progres-
sion, however the definition of the FCR covers both. More-
over, this is a longitudinal study that will follow patients with
HNC through the years, and thus, for some patients, fear of
progression will become fear of recurrence over time.
Albeit time since diagnosis was known, time of completing
the questionnaires and interviews in relation to the multi-
disciplinary treatment planning meeting (in which prognosis is
often discussed) was not known from the existing data set.
This is relevant because it is not known to what extent patients
were fully aware of their objective risk of recurrence at the
time of completing the baseline questionnaire and interviews.
Future NET-QUBIC reports will also report on the association
between treatment type and FCR, since two recent meta-
analyses reported that both chemotherapy and radiotherapy are
significant predictors of high FCR,60,61 although none of ana-
lyses were specifically made on patients with HNC. Another
interesting question that will be explored in emerging prospec-
tive data is how FCR and cancer survival are related. Previous
studies have only reported about the potential relationship
between more global psychological distress (mainly depres-
sion) and disease progression/recurrence and mortality.62 Liter-
ature reviews suggest a small/moderate effect of psychological
distress on cancer prognosis,63 however no data to this date
are available on the relationship between FCR and survival.
In conclusion, approximately one in two of all patients
newly diagnosed with HNC had FCR levels above the vali-
dated cutoff for high FCR shortly after diagnosis. As previ-
ously reported in other studies,45 FCR was not associated
with tumor-related characteristics, however higher FCR were
found to be associated with being younger, more introverted,
having higher symptoms of anxiety, more unmet needs for
help with sexuality issues, and being an exsmoker.
For clinicians working with patients with HNC, these data
help to raise awareness of the high prevalence of FCR in
patients newly diagnosed with HNC. High FCR can some-
times be associated with hypervigilance for symptoms,
overuse of medical testing, and/or avoidance of recommended
medical investigations.13 A better understanding and detection
of high FCR might encourage clinicians to tell patients about
this and promote more appropriate follow-up and cancer sur-
veillance in vulnerable individuals. Brief screening tools for
FCR including some specifically developed for the HNC set-
ting (eg, Patients Concern Inventory; and a single-item
screener)64 are available and may assist clinicians to identify
patients with HNC with high FCR who might benefit from
new evidence-based psychological interventions65,66 for severe
and disabling FCR.
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